Navigation Links
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to improve the gastrointestinal safety of antiplatelet therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. "In a previous clinical trial we demonstrated that the absorption of CGT-2168 is equivalent to that of Plavix, and that the omeprazole component within CGT-2168 does not interfere with the metabolism of the clopidogrel component," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

An independent study published this week in the Journal of the American College of Cardiology showed that commercially available omeprazole significantly decreases the antiplatelet activity of Plavix when the two medicines are co-administered. "This finding is consistent with our own earlier clinical data that revealed an adverse drug interaction between Plavix and Prilosec(R) (marketed omeprazole), and may raise serious concerns for patients and practitioners," Dr. Goldsmith said. "However, these findings contrast with the properties we have observed with our unique formulation, CGT-2168. We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today."

Separately, Cogentus has begun COGENT-1, a global Phase 3 trial that will evaluate the clinical benefits of CGT-2168 with aspirin compared to Plavix with aspirin. COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

While antiplatelet therapy has been shown to be effective in preventing major cardiovascular events, it is associated with significant gastrointestinal side effects including bleeding, which can interrupt treatment, may require hospitalization or in some cases even result in death. A study recently published in the Annals of Internal Medicines concluded that the antiplatelet drugs aspirin and clopidogrel are, respectively, the third and fourth most common causes of U.S. emergency room visits by older adults experiencing adverse drug events.

"Because of potentially important safety and efficacy concerns surrounding antiplatelet therapy, Cogentus is investing significantly in completing the testing of our next-generation medicine that may provide patients and physicians with a treatment option that preserves the full cardiovascular benefits while minimizing potentially dangerous side effects," Dr. Goldsmith said.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.

Prilosec(R) is a registered trademark of AstraZeneca AB.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):